City of Hope

Latest from City of Hope

Dr Joel W. Neal: Cabozantinib/Atezolizumab May Fullfill Unmet Targeted Treatment Need in NSCLC

June 06, 2022

Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.

ASCT Early in Multiple Myeloma Treatment Improves PFS, but OS Same as RVd

June 06, 2022

Results presented at the American Society of Clinical Oncology Annual Meeting showed a 21.4-month advantage for autologous stem cell transplant (ASCT) over a common triplet therapy in progression-free survival (PFS) but no advantage in overall survival (OS).

Redefining Cancer Care: Putting Equity, Quality, and Patients at the Center

April 17, 2022

The fight to improve cancer care includes aspects of both equity and quality. Over the past decade, health insurance coverage has been expanded to millions of previously uninsured Americans, but there is evidence that not every patient has the same access or the same quality of care.

City of Hope’s Alvarnas: Payers Must Recognize Cancer Care Is Different

April 17, 2022

Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.